T
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Timothy C. Chambers' research focuses on understanding and developing therapeutic strategies for various cancers, with a particular emphasis on cancer stem-like cells and drug resistance mechanisms. His work has investigated the anti-cancer activity of compounds such as monensin and salinomycin analogs, exploring their efficacy in both 2D and 3D models of breast and glioblastoma. Chambers has also studied the synthesis and anticancer potential of novel colchicine derivatives.
Further investigations include examining the susceptibility of primary acute lymphoblastic leukemia cells to microtubule depolymerization and exploring distinct cell death pathways. His research group collaborates with other faculty members at the University of Arkansas for Medical Sciences, including Joshua M. Eichhorn, Alicja Urbaniak, Megan R. Reed, and Billie Heflin, on projects related to these areas. Chambers' scholarship is recognized by a high h-index of 35 and over 4,600 citations across 168 publications, indicating significant impact in his field.
Metrics
- h-index: 35
- Publications: 168
- Citations: 4,682
Selected Publications
-
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG (2025)
-
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025)
-
Data from Key role for Bak activation and Bak-Bax interaction in the apoptotic response to vinblastine (2023)
-
Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer (2022)
-
Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer (2022)
-
Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways (2022)
-
Phosphoproteomics Provides Novel Insights into the Response of Primary Acute Lymphoblastic Leukemia Cells to Microtubule Depolymerization in G1 Phase of the Cell Cycle (2021)
-
Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models (2021)
-
Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs (2021)
-
Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives (2021)
Collaboration Network
Top Collaborators
Anisha Kothari
36 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Figure S2 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S5 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S1 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S4 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 36 shared publications
Walter N. Hittelman
22 shared publications
- Figure S2 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S5 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S1 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S4 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
- Figure S3 from Cell Cycle–Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 22 shared publications
Sarah E. Alford
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Floris C. Loeff
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Joshua M. Eichhorn
14 shared publications
In database
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Nandini Sakurikar
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Henriëtte M. Goselink
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Robert L. Saylors
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Inge Jedema
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
J.H. Frederik Falkenburg
14 shared publications
- Supplemental Figure 1 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 5 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplementary Material from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 3 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- Supplemental Figure 2 from BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Showing 5 of 14 shared publications
Alicja Urbaniak
University of Arkansas for Medical Sciences
8 shared publications
In database
- Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives
- Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways
- Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs
Showing 5 of 8 shared publications
Adam Huczyński
Adam Mickiewicz University in Poznań (PL)
6 shared publications
- Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives
- Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs
- Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer
Showing 5 of 6 shared publications
Megan R. Reed
University of Arkansas for Medical Sciences
6 shared publications
In database
- Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Primary acute lymphoblastic leukemia cells are susceptible to microtubule depolymerization in G1 and M phases through distinct cell death pathways
- Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs
- Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer
Showing 5 of 6 shared publications
Robert L. Eoff
University of Arkansas for Medical Sciences
5 shared publications
In database
- Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs
- Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer
- Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model
Angus M. MacNicol
University of Arkansas for Medical Sciences
5 shared publications
In database
- Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer
- Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models
- Abstract PS18-46: Inhibition of breast cancer stem cells in 2- and 3-dimensional culture by novel salinomycin analogs
- Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer
- Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model
Similar Researchers
Based on overlapping research topics
Sarah Heflin
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Breast Cancer Treatment Studies
Bryan E. White
University of Arkansas at Little Rock
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Breast Cancer Treatment Studies
Zhixing Wang
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Drug Transport and Resistance Mechanisms
Hong-yu Li
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Drug Transport and Resistance Mechanisms
Veronica Piedra
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Drug Transport and Resistance Mechanisms
Shi‐Ming Tu
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Mesenchymal stem cell research